At the last check on Friday, bluebird bio Inc.’s (NASDAQ:BLUE) stock was down -$0.07, moving down -0.93 percent to $7.45. The average number of shares traded per day over the past five days has been 2,108,458 shares. 2 times new highs have been achieved over the past 5 days, with a $0.47 gain in that time frame. In the last twenty days, the average volume was 3,807,724, while in the previous 50 days, it was 5,813,570.
Since last month, BLUE stock rose 21.88%. Shares of the company fell to $5.79 on 10/28/22, the lowest level in the past month. A 52-week high of $11.70 was reached on 01/04/22 after having rallying from a 52-week low of $2.87. Since the beginning of this year, BLUE’s stock price has dropped by -24.72% or -$2.50, and marked a new high 2 times. However, the stock has declined by -36.32% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
BLUE stock investors should be aware that bluebird bio Inc. (BLUE) stock had its last reported insider trading activity 21 days ago on Nov 04. Obenshain Andrew, the President and CEO of the company, disposed of 1,263 shares for $6.41 on Nov 04. It resulted in a $8,101 divestment by the insider. Colvin Richard A sold 218 shares at an average price of $6.41 on Nov 04. The insider now owns 74,788 shares following the transaction. On Aug 19, Chief Strategy & Financial Off Cole Jason sold 14,194 shares at $5.53 apiece. The transaction was valued at $78,473.
The stock’s beta is 0.94. Besides these, the trailing price-to-sales (P/S) ratio of 122.94, the price-to-book (PB) ratio of 3.86.
Based on annual data, BLUE earned -$35.2 million in gross profit and brought in $3.66 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BLUE’s revenue fell -10571.43% to $1.52 million during the quarter, while net income inched up to $70000.0. While analysts expected bluebird bio Inc. to report -$1.24 quarterly earnings, the actual figure was -$1.36 per share, beating the consensus estimate by -9.70%. During the quarter, the company generated -$83.39 million in EBITDA. The liabilities of bluebird bio Inc. were 361.24 million at the end of its most recent quarter ended June 29, and its total debt was $292.97 million. The value of shareholders’ equity is $82.91 million.
This quick technical analysis looks at bluebird bio Inc.’s (BLUE) price momentum. With a historical volatility rate of 67.20%, the RSI 9-day stood at 59.57% on 23 November.
With respect to its five-day moving average, the current bluebird bio Inc. price is up by +6.70% percent or $0.47. At present, BLUE shares trade +24.63% above its 20-day simple moving average and +55.39% percent above its 100-day simple moving average. However, the stock is currently trading approximately +5.64% above its SMA50 and +4.90% above its SMA200.
Stochastic coefficient K was 71.23% and Stochastic coefficient D was 63.97%, while ATR was 0.57. Given the Stochastic reading of 68.61% for the 14-day period, the RSI (14) reading has been calculated as 57.68%. As of today, the MACD Oscillator reading stands at 0.12, while the 14-day reading stands at 0.21.
Barclays upgraded its rating on bluebird bio Inc. (NASDAQ: BLUE) to an Equal weight in a note to investors on August 05, 2022. The analysts firm previously had an Underweight rating on the stock.bluebird bio Inc. (BLUE) has been rated Hold by analysts. According to 2 brokerage firms, BLUE is a sell, and 8 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate bluebird bio Inc. stock as buy, with 0 recommending it as overweight.